Doximity, Inc. Class A Common Stock (DOCS)

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. (“Doximity” or “the Company”) (NYSE: DOCS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between August 8, 2024 and May 13, 2026. Doximity describes itself as a “digital platform for medical professionals that combines health care news, workflow products, and clinician networking.”

Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) filed a class action in the U.S. District Court for the Northern District of California alleging violations of the federal securities laws by Doximity, Inc. (“Doximity” or the “Company”) and certain of the Company’s current and former senior executives (collectively, “Defendants”). The action is brought on behalf of all investors who purchased or otherwise acquired Doximity common stock between August 8, 2024, and May 13, 2026, inclusive (the “Class Period”).

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Doximity, Inc. (NYSE: DOCS) common stock August 8, 2024 and May 13, 2026, inclusive (the Class Period). Doximity is a digital platform for medical professionals that combines health care news, workflow products, and clinician networking.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are finding an unexpected source of optimism in AI. Rather than viewing the technology as a threat, nearly a quarter expect it to increase their total compensation within the next year, and two-thirds believe staying current with AI will give them a meaningful earnings edge over peers who don't.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 first quarter ended June 30, 2026.

Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2026 after market close on August 6, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Doximity Ask, its HIPAA-compliant clinical AI platform, outperformed leading frontier AI models in the NOHARM (Numerous Options Harm Assessment for Risk in Medicine) benchmark, one of the most comprehensive independent evaluations of clinical AI safety to date.

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or “the Company”) (NYSE: DOCS) for violations of the securities laws.

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 4:40 p.m. Central Time.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced an integration with Aledade, a physician‑led, national leader in value‑based care. Through the agreement, Doximity will integrate components of its HIPAA-compliant Clinical AI Suite, including its ambient notetaking tool Scribe and clinical AI assistant Ask (formerly DoxGPT), into Aledade Assist™, Aledade’s EHR overlay that surfaces clinical insights at the point of care.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 fourth quarter and fiscal year ended March 31, 2026.

Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 after market close on May 13, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released a new report examining how physicians are adopting artificial intelligence (AI) in clinical practice. The findings show that AI adoption and interest are widespread: 94% of physicians reported they are currently using AI or interested in doing so. At the same time, physicians remain cautious, with 71% citing accuracy and reliability as their top concern.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?